Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of KX01 Ointment 1% in Japanese Adults with Actinic Keratosis on the Face or Scalp
jRCT2031210447Phase 3Active, not recruiting
- Sponsor
- PharmaEssentia
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing KX01 ointment 1% with Vehicle ointment (2 arms). Primary endpoints: Safety (adverse events and safety evaluations) and Pharmacokinetics of KX01. Started Dec 2021; status: active, not recruiting.
02
Drugs
tirbanibulin
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on jRCT2031210447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210447.